LOS ANGELES, February 13, 2018 /PRNewswire/ --
GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA)
announced today that Dr. Jeffrey
Miller, Deputy Director of the Masonic Cancer Center,
University of Minnesota will be
presenting at the Keystone Symposia: Emerging Cellular Therapies: T
Cells and Beyond; 'Novel Ways to Activate and Target NK Cells to
Treat Cancer'. This presentation will highlight
GT Biopharma's TriKE and TetraKE platforms.
Dr. Miller will be presenting to leaders in the field of cell
therapies at the conference on Feb.
14th from 5:00 -7:00 pm MT. He
will be discussing GT Biopharma's unique single-chain, tri-specific
NK cell engager (TriKE) and tetra-specific NK cell engager
(TetraKE) platforms targeting hematologic malignancies, sarcomas
and carcinomas (solid tumors). The presentation will address both
the TriKE and TetraKE constructs, as well as our second-generation
anti-CD16-IL-15-anti-CD33 TriKE (OXS-C3550); another
first-of-its-kind, single-chain, tri-specific NK cell engager
(TriKE).
NK cell cancer-killing activity is expected to be increased by
bringing the NK cells in close proximity to the cancer cells. This
may be achieved by 'engagers' that bind to CD16 on the surface of
NK cells and bind specific proteins (such as CD33) on the surface
of cancer cells, thus forming an immune synapse between the NK cell
and the cancer cell. Our lead TriKE, anti-CD16-IL-15-anti-CD33
(OXS-3550) is expected to be in the clinic in the second half of
2018. The TriKE constructs utilize the inclusion of interleukin-15
(IL-15), a peptide that leads to proliferation and activation of
the NK cells. This further increases NK cancer-cell killing
capabilities and improves their function in the tumor
microenvironment (Vallera et al,2016).
Unlike traditional CAR-T platforms, TriKEs are potentially a
cost effective cell therapy and not relegated to treating liquid
tumors only. GT Biopharma believes that TriKEs are an antibody
platform that can be tailored to treat any form of cancer, liquid
or solid tumors.
Dr. Jeffrey Miller said, "I am
pleased to present additional information regarding these
immune-oncology platforms. As a researcher, I continue to believe
that both have the potential to generate candidates with the
ability to have a significant impact on the treatment of cancer and
other diseases."
GT Biopharma Chief Medical officer (CMO) Dr. Raymond Urbanski said, "The TriKE and TetraKE
concepts and constructs potentially have significant advantages
over current and other development-stage therapies. Dr. Miller is a
luminary in NK cell biology and its applications, and we continue
to be excited by the potential opportunity related to this
technology."
About GT Biopharma, Inc.:
GT Biopharma, Inc. is a biotechnology company focused on
innovative drugs for the treatment of cancer. GT's lead oncology
drug candidate, OXS-1550 (DT2219) is a novel bispecific scFv
recombinant fusion protein-drug conjugate composed of the variable
regions of the heavy and light chains of anti-CD19 and anti-CD22
antibodies and a modified form of diphtheria toxin as its cytotoxic
drug payload. OXS-1550 targets cancer cells expressing the CD19
receptor or the CD22 receptor or both receptors. When OXS-1550
binds to cancer cells, the cancer cells internalize the drug and
are killed due to the action of cytotoxic payload. OXS-1550 has
demonstrated success in early human clinical trials in patients
with relapsed/refractory B-cell lymphoma or leukemia. In addition,
GTs TriKE platform will address a number of cancer types. GT's
nervous system platform is focused on acquiring or discovering and
patenting late-stage, de-risked, and close-to-market improved
treatments for nervous system diseases (Neurology and Pain) and
shepherding them through the approval process to the NDA. GT
Biopharma's neurology products currently include PainBrake, as well
as treatments for the symptoms of myasthenia gravis, and motion
sickness.
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the payment of dividends, marketing and distribution
plans, development activities and anticipated operating results.
Factors which could cause actual results to differ materially from
these forward-looking statements include such factors as the
Company's ability to accomplish its business initiatives,
significant fluctuations in marketing expenses and ability to
achieve and expand significant levels of revenues, or recognize net
income, from the sale of its products and services, as well as the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Company website: http://www.GTBiopharma.com
Contact:
Westwicke Partners
John Woolford
+1(443)213-0506
john.woolford@westwicke.com
SOURCE GT Biopharma Inc.